Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

RINVOQ LQ

UPADACITINIB

Standard Dose
1MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview RINVOQ LQ is listed in Drugs@FDA under application 218347 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient UPADACITINIB Form and strength SOLUTION;ORAL - 1MG/ML Sponsor ABBVIE Submission history Latest submission status date: 2025-10-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview RINVOQ LQ is listed in Drugs@FDA under application 218347 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient UPADACITINIB Form and strength SOLUTION;ORAL - 1MG/ML Sponsor ABBVIE Submission history Latest submission status date: 2025-10-10 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.